Incannex (Nasdaq: IXHL) announced that Alliance Global Partners has initiated equity research coverage with a BUY rating and a US$18.00 price target, in a report dated June 8, 2026 by analyst James Molloy.
The coverage evaluates Incannex’s clinical pipeline, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and is expected by the company to broaden investor awareness. AGP has received compensation from Incannex for investment banking services.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
AGP price target US$18.00 per share Alliance Global Partners research report dated June 8, 2026
$3.40 Last Close
Volume Volume 831,511 is 3.19x the 20-day average of 260,998, signaling elevated interest ahead of this note. high
Technical Shares at $3.40 are trading below the 200-day MA of $9.21, reflecting a longer-term downtrend despite the recent bounce.
Sector move flag is false. Two peers in momentum scanner, GELS up 4.15% and RMTI up 11.91%, but the target’s direction is unspecified, so alignment with IXHL’s move cannot be determined.
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Clinical trial start | Positive | +0.8% | DReAMzz dose-optimization study for IHL-42X officially commenced across 14 clinical sites. |
| May 12 | Award recognition | Positive | -13.9% | MedTech Breakthrough award for IHL-42X as best new drug development technology. |
| Apr 22 | Regulatory alignment | Positive | +4.4% | PSX-001 Phase 2 data and alignment with White House order on psychedelic treatments. |
| Mar 27 | Share repurchase | Positive | -5.0% | Reactivation of share repurchase program supported by strong cash and no debt. |
| Mar 25 | Research partnership | Positive | +15.8% | Partnership with AASM Foundation to back sleep apnea research alongside IHL-42X progress. |
Pattern Detected
Recent positive milestones have produced mixed reactions, with some clinical and partnership updates aligning with upside moves and others seeing selling pressure despite constructive news.
Recent Company History
Over recent months, Incannex has advanced lead programs and corporate positioning. On Mar 25, it announced an AASM Foundation partnership tied to IHL-42X and broader pipeline work, followed by a share repurchase reactivation on Mar 27. In April and May, the company highlighted strong PSX-001 Phase 2 data, a MedTech Breakthrough award, and formal commencement of the DReAMzz IHL-42X study. Today’s AGP research coverage fits into this sequence of efforts to showcase clinical progress and strategy to the market.
This announcement highlights initiation of independent coverage by Alliance Global Partners, including a BUY rating and US$18.00 price target, focused on Incannex’s IHL-42X and PSX-001 programs. It follows recent milestones such as DReAMzz trial initiation and external recognition for IHL-42X. Investors may watch how future trial updates, cash usage, and any additional analyst coverage evolve relative to these earlier clinical, financial, and strategic disclosures when assessing the company’s trajectory.
equity research coverage financial
“Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company.”
Equity research coverage is when professional analysts regularly study a publicly traded company and publish reports that explain its business health, future prospects, and numerical forecasts. Like having a coach who watches a team closely and issues game plans and rankings, this coverage gives investors independent information, ratings and expectations that can affect a stock’s visibility, trading volume and perceived value.
price target financial
“Research Coverage Highlights Rating: BUYPrice Target: US$18.00 per shareAnalyst:”
A price target is an analyst’s estimate of the future value of a stock, typically expressed as a single number for a set time frame. It matters to investors because it acts like an expected selling price when appraising a house—helping people decide whether a stock looks cheap, fairly priced, or expensive compared with current market price and guiding buy, hold or sell decisions; it is an opinion, not a guarantee.
psilocybin medical
“PSX-001, the Company’s synthetic psilocybin program for generalized anxiety disorder.”
A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.
generalized anxiety disorder medical
“synthetic psilocybin program for generalized anxiety disorder.”
Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.
investment banking services financial
“Alliance Global Partners has received compensation from Incannex for providing investment banking services.”
Investment banking services are professional financial services that help companies raise money, buy or sell businesses, and arrange large financial transactions. They act like architects and matchmakers—designing funding plans, finding investors or buyers, and negotiating terms—so investors pay attention because these services shape a company’s capital, ownership, and the potential returns and risks tied to its stock or bonds.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to announce that Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company.
The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex’s clinical pipeline, development strategy, market opportunities and future growth prospects.
Research Coverage Highlights
- Rating: BUY
- Price Target: US
$18.00 per share - Analyst: James Molloy, Alliance Global Partners
- Report Date: June 8, 2026
Incannex believes the initiation of coverage by AGP represents an important milestone in expanding awareness of the Company’s clinical programs and investment proposition among institutional and retail investors.
The report includes discussion of the Company’s lead obstructive sleep apnoea program, IHL-42X, currently being advanced through the DReAMzz dose optimisation study, as well as PSX-001, the Company’s synthetic psilocybin program for generalized anxiety disorder.
Joel Latham, President and Chief Executive Officer of Incannex, commented:
“We are pleased AGP has elected to initiate research coverage and appreciate the time and diligence their team has dedicated to understanding our business, clinical programs and long-term strategy.”
“As we continue advancing IHL-42X and PSX-001 through development, we believe increased research coverage can help broaden investor awareness of the significant unmet needs we are seeking to address and the substantial commercial opportunities represented by our pipeline.”
Investors may contact Alliance Global Partners (www.allianceg.com) directly to obtain a copy of the report.
Analyst Disclaimer
The information above regarding analyst coverage is solely for informational purposes and is not intended as a solicitation to make investments. Any opinions, estimates or forecasts regarding Incannex’s performance made by analysts are theirs alone and do not represent opinions, forecasts or predictions of Incannex or its management. Incannex does not by its reference above, or by distribution, imply its endorsement of or concurrence with such information, conclusions or recommendations. Alliance Global Partners has received compensation from Incannex for providing investment banking services. Incannex undertakes no obligation to update or revise any such information, conclusions or recommendations, whether as a result of new information, future events or otherwise.
About Incannex Healthcare Inc.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the development, regulatory progress and commercialization of the Company’s drug candidates, potential benefits of equity research coverage, the potential value of the Company’s drug candidates and business, and potential shareholder value. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, the potential risk that equity research coverage may not result in increased investor awareness or liquidity, risks associated with the clinical development of IHL-42X and PSX-001, and other risks described in the section entitled “Risk Factors” described in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au
FAQ
What research coverage did Alliance Global Partners initiate on Incannex (Nasdaq: IXHL) in June 2026?
Alliance Global Partners initiated equity research coverage on Incannex with a BUY rating and a US$18.00 price target. According to Incannex, the June 8, 2026 report reviews the company’s clinical pipeline, development strategy, market opportunities, and future growth prospects.
What is Alliance Global Partners’ price target for Incannex (IXHL) and who is the analyst?
Alliance Global Partners set a US$18.00 per share price target on Incannex, with a BUY rating. According to Incannex, the coverage was authored by James Molloy, Managing Director and Senior Biotechnology Analyst at Alliance Global Partners, dated June 8, 2026.
Which Incannex drug candidates are highlighted in the new Alliance Global Partners research on IXHL?
The research highlights IHL-42X for obstructive sleep apnoea and PSX-001, a synthetic psilocybin program for generalized anxiety disorder. According to Incannex, IHL-42X is in the DReAMzz dose optimisation study and PSX-001 targets significant unmet mental health needs.
How does Incannex expect the Alliance Global Partners coverage to impact IXHL investors?
Incannex expects the research coverage to expand awareness of its clinical programs and investment proposition among institutional and retail investors. According to Incannex, greater analyst coverage may help investors understand the company’s pipeline, development strategy, and the commercial opportunities it believes its programs represent.
Where can investors obtain the Alliance Global Partners research report on Incannex (IXHL)?
Investors can contact Alliance Global Partners directly to request the Incannex research report. According to Incannex, the information about analyst coverage is provided for informational purposes only and is not intended as an investment solicitation or an endorsement of the report’s conclusions.
